Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Davila

Showing results (91-100 of 124) with videos related to

Pageof 13
Sort By:
Transplantation and Cellular Therapy|March 30, 2021
Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell LymphomaAbu-Sayeef Mirza, Ambuj Kumar, Hamza Hashmi, et al.
Blood Advances|July 24, 2020
High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphomaErin A Dean, Rahul S Mhaskar, Hong Lu, et al.
The Journal of Clinical Investigation|October 30, 2025
IFN-γ-driven skewing towards Th1 over Th17 differentiation underlies CRS and neutropenia in CAR-T therapyPayal Goala, Yongliang Zhang, Nolan Beatty, et al.
International Journal of Molecular Sciences|May 7, 2025
Intravenous Immunoglobulin (IVIG) for Patients with Severe Neurotoxicity Associated with Chimeric Antigen Receptor T-Cell (CAR-T) TherapySepideh Mokhtari, Justin M Asquith, Syeda Saba Kareem, et al.
The Lancet. Haematology|February 10, 2023
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trialDavid A Sallman, Tessa Kerre, Violaine Havelange, et al.
Molecular Therapy. Methods & Clinical Development|September 14, 2018
Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository ExperienceKenneth Cornetta, Lisa Duffy, Steven A Feldman, et al.
Transplantation and Cellular Therapy|March 30, 2021
ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell TransplantationDoris K Hansen, Jongphil Kim, Zachary Thompson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2021
Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial ResultsJoseph Pidala, Kelly Walton, Hany Elmariah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2023
Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict MortalityShernan G Holtan, Constanza Savid-Frontera, Kelly Walton, et al.
Cardio-Oncology (London, England)|April 3, 2023
Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory studyDae Hyun Lee, Sanjay Chandrasekhar, Michael D Jain, et al.
Pageof 13

Showing results (91-100 of 124) with videos related to

Sort By:
Pageof 13
Transplantation and Cellular Therapy|March 30, 2021
Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell LymphomaAbu-Sayeef Mirza, Ambuj Kumar, Hamza Hashmi, et al.
Blood Advances|July 24, 2020
High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphomaErin A Dean, Rahul S Mhaskar, Hong Lu, et al.
The Journal of Clinical Investigation|October 30, 2025
IFN-γ-driven skewing towards Th1 over Th17 differentiation underlies CRS and neutropenia in CAR-T therapyPayal Goala, Yongliang Zhang, Nolan Beatty, et al.
International Journal of Molecular Sciences|May 7, 2025
Intravenous Immunoglobulin (IVIG) for Patients with Severe Neurotoxicity Associated with Chimeric Antigen Receptor T-Cell (CAR-T) TherapySepideh Mokhtari, Justin M Asquith, Syeda Saba Kareem, et al.
The Lancet. Haematology|February 10, 2023
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trialDavid A Sallman, Tessa Kerre, Violaine Havelange, et al.
Molecular Therapy. Methods & Clinical Development|September 14, 2018
Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository ExperienceKenneth Cornetta, Lisa Duffy, Steven A Feldman, et al.
Transplantation and Cellular Therapy|March 30, 2021
ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell TransplantationDoris K Hansen, Jongphil Kim, Zachary Thompson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2021
Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial ResultsJoseph Pidala, Kelly Walton, Hany Elmariah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2023
Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict MortalityShernan G Holtan, Constanza Savid-Frontera, Kelly Walton, et al.
Cardio-Oncology (London, England)|April 3, 2023
Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory studyDae Hyun Lee, Sanjay Chandrasekhar, Michael D Jain, et al.
Pageof 13